Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
The immunodeficiency-cancer registry is renewed.

Immunology today

Filopovich AH, Stoker V.
PMID: 25290748
Immunol Today. 1984 Nov;5(11):309. doi: 10.1016/0167-5699(84)90117-8.

No abstract available.

Cite
Filopovich AH, Stoker V. The immunodeficiency-cancer registry is renewed. Immunol Today. 1984;5(11):309doi: 10.1016/0167-5699(84)90117-8.
Filopovich, A. H., & Stoker, V. (1984). The immunodeficiency-cancer registry is renewed. Immunology today, 5(11), 309. https://doi.org/10.1016/0167-5699(84)90117-8
Filopovich, A H, and Stoker, V. "The immunodeficiency-cancer registry is renewed." Immunology today vol. 5,11 (1984): 309. doi: https://doi.org/10.1016/0167-5699(84)90117-8
Filopovich AH, Stoker V. The immunodeficiency-cancer registry is renewed. Immunol Today. 1984 Nov;5(11):309. doi: 10.1016/0167-5699(84)90117-8. PMID: 25290748.
Copy Download .nbib Format: NLM
High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia.

Hematology reports

Erdfelder F, Hertweck M, Filipovich A, Uhrmacher S, Kreuzer KA.
PMID: 22184516
Hematol Rep. 2010 Jan 26;2(1):e3. doi: 10.4081/hr.2010.e3. Epub 2010 May 06.

We determined lymphoid enhancer-binding factor-1 (LEF1) mRNA expression in 112 chronic lymphocytic leukemia (CLL) samples and assessed correlations with the prognostic markers ZAP70 and CD38, Binet stages, the percentage of lymphocytes in the peripheral blood, and fibromodulin (FMOD) transcripts....

Cite
Erdfelder F, Hertweck M, Filipovich A, et al. High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematol Rep. 2010;2(1):e3doi: 10.4081/hr.2010.e3.
Erdfelder, F., Hertweck, M., Filipovich, A., Uhrmacher, S., & Kreuzer, K. A. (2010). High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematology reports, 2(1), e3. https://doi.org/10.4081/hr.2010.e3
Erdfelder, Felix, et al. "High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia." Hematology reports vol. 2,1 (2010): e3. doi: https://doi.org/10.4081/hr.2010.e3
Erdfelder F, Hertweck M, Filipovich A, Uhrmacher S, Kreuzer KA. High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematol Rep. 2010 Jan 26;2(1):e3. doi: 10.4081/hr.2010.e3. Epub 2010 May 06. PMID: 22184516; PMCID: PMC3222268.
Copy Download .nbib Format: NLM
Erratum to "Bortezomib for Refractory Autoimmunity in Pediatrics" [Biol Blood Marrow Transplant 2014;20(10):1654-1659].

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH.
PMID: 27179942
Biol Blood Marrow Transplant. 2016 Jun;22(6):1147. doi: 10.1016/j.bbmt.2015.11.014. Epub 2015 Nov 28.

No abstract available.

Cite
Khandelwal P, Davies SM, Grimley MS, et al. Erratum to "Bortezomib for Refractory Autoimmunity in Pediatrics" [Biol Blood Marrow Transplant 2014;20(10):1654-1659]. Biol Blood Marrow Transplant. 2015;22(6):1147doi: 10.1016/j.bbmt.2015.11.014.
Khandelwal, P., Davies, S. M., Grimley, M. S., Jordan, M. B., Curtis, B. R., Jodele, S., Marsh, R., & Filipovich, A. H. (2016). Erratum to "Bortezomib for Refractory Autoimmunity in Pediatrics" [Biol Blood Marrow Transplant 2014;20(10):1654-1659]. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 22(6), 1147. https://doi.org/10.1016/j.bbmt.2015.11.014
Khandelwal, Pooja, et al. "Erratum to "Bortezomib for Refractory Autoimmunity in Pediatrics" [Biol Blood Marrow Transplant 2014;20(10):1654-1659]." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation vol. 22,6 (2016): 1147. doi: https://doi.org/10.1016/j.bbmt.2015.11.014
Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH. Erratum to "Bortezomib for Refractory Autoimmunity in Pediatrics" [Biol Blood Marrow Transplant 2014;20(10):1654-1659]. Biol Blood Marrow Transplant. 2016 Jun;22(6):1147. doi: 10.1016/j.bbmt.2015.11.014. Epub 2015 Nov 28. PMID: 27179942.
Copy Download .nbib Format: NLM
Elevated Granzyme B in Cytotoxic Lymphocytes is a Signature of Immune Activation in Hemophagocytic Lymphohistiocytosis.

Frontiers in immunology

Mellor-Heineke S, Villanueva J, Jordan MB, Marsh R, Zhang K, Bleesing JJ, Filipovich AH, Risma KA.
PMID: 23524976
Front Immunol. 2013 Mar 22;4:72. doi: 10.3389/fimmu.2013.00072. eCollection 2013.

Patients with hemophagocytic lymphohistiocytosis (HLH) exhibit immune hyper-activation as a consequence of genetic defects in secretory granule proteins of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. Murine models of HLH demonstrate significant activation of CTL as central...

Cite
Mellor-Heineke S, Villanueva J, Jordan MB, et al. Elevated Granzyme B in Cytotoxic Lymphocytes is a Signature of Immune Activation in Hemophagocytic Lymphohistiocytosis. Front Immunol. 2013;4:72doi: 10.3389/fimmu.2013.00072.
Mellor-Heineke, S., Villanueva, J., Jordan, M. B., Marsh, R., Zhang, K., Bleesing, J. J., Filipovich, A. H., & Risma, K. A. (2013). Elevated Granzyme B in Cytotoxic Lymphocytes is a Signature of Immune Activation in Hemophagocytic Lymphohistiocytosis. Frontiers in immunology, 472. https://doi.org/10.3389/fimmu.2013.00072
Mellor-Heineke, Sabine, et al. "Elevated Granzyme B in Cytotoxic Lymphocytes is a Signature of Immune Activation in Hemophagocytic Lymphohistiocytosis." Frontiers in immunology vol. 4 (2013): 72. doi: https://doi.org/10.3389/fimmu.2013.00072
Mellor-Heineke S, Villanueva J, Jordan MB, Marsh R, Zhang K, Bleesing JJ, Filipovich AH, Risma KA. Elevated Granzyme B in Cytotoxic Lymphocytes is a Signature of Immune Activation in Hemophagocytic Lymphohistiocytosis. Front Immunol. 2013 Mar 22;4:72. doi: 10.3389/fimmu.2013.00072. eCollection 2013. PMID: 23524976; PMCID: PMC3605512.
Copy Download .nbib Format: NLM
Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations.

Cytometry. Part B, Clinical cytometry

Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA.
PMID: 26305518
Cytometry B Clin Cytom. 2014 Feb 07; doi: 10.1002/cytob.21166. Epub 2014 Feb 07.

INTRODUCTION: X-linked lymphoproliferative disease is caused by mutations in 2 genes, SH2D1A and XIAP/BIRC4. Flow cytometric methods have been developed to detect the gene products, SAP and XIAP. However, there is no literature describing the accuracy of flow cytometric...

Cite
Gifford CE, Weingartner E, Villanueva J, et al. Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations. Cytometry B Clin Cytom. 2014;doi: 10.1002/cytob.21166.
Gifford, C. E., Weingartner, E., Villanueva, J., Johnson, J., Zhang, K., Filipovich, A. H., Bleesing, J. J., & Marsh, R. A. (2014). Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations. Cytometry. Part B, Clinical cytometry, . https://doi.org/10.1002/cytob.21166
Gifford, Carrie E, et al. "Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations." Cytometry. Part B, Clinical cytometry vol. (2014). doi: https://doi.org/10.1002/cytob.21166
Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA. Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations. Cytometry B Clin Cytom. 2014 Feb 07; doi: 10.1002/cytob.21166. Epub 2014 Feb 07. PMID: 26305518.
Copy Download .nbib Format: NLM
B-lymphocyte function in immunodeficiency disease.

Immunology today

Filipovich AH, Kersey JH.
PMID: 25291070
Immunol Today. 1983 Feb;4(2):50-5. doi: 10.1016/0167-5699(83)90111-1.

While B lymphocytes were originally named after their developmental site in the bursa of, Fabricius of chickens, it is currently accepted that bone marrow is the primary site of early events in the differentiation of postnatal B lymphocytes in...

Cite
Filipovich AH, Kersey JH. B-lymphocyte function in immunodeficiency disease. Immunol Today. 1983;4(2):50-5doi: 10.1016/0167-5699(83)90111-1.
Filipovich, A. H., & Kersey, J. H. (1983). B-lymphocyte function in immunodeficiency disease. Immunology today, 4(2), 50-5. https://doi.org/10.1016/0167-5699(83)90111-1
Filipovich, A H, and Kersey, J H. "B-lymphocyte function in immunodeficiency disease." Immunology today vol. 4,2 (1983): 50-5. doi: https://doi.org/10.1016/0167-5699(83)90111-1
Filipovich AH, Kersey JH. B-lymphocyte function in immunodeficiency disease. Immunol Today. 1983 Feb;4(2):50-5. doi: 10.1016/0167-5699(83)90111-1. PMID: 25291070.
Copy Download .nbib Format: NLM
Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.

The application of clinical genetics

Buchbinder D, Nugent DJ, Fillipovich AH.
PMID: 24817816
Appl Clin Genet. 2014 Apr 03;7:55-66. doi: 10.2147/TACG.S58444. eCollection 2014.

Wiskott-Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency disorder characterized by the triad of eczema, thrombocytopenia, and severe and often recurrent infections. Despite the rarity of this disorder, our understanding of the molecular and cellular pathogenesis of WAS...

Cite
Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55-66doi: 10.2147/TACG.S58444.
Buchbinder, D., Nugent, D. J., & Fillipovich, A. H. (2014). Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. The application of clinical genetics, 755-66. https://doi.org/10.2147/TACG.S58444
Buchbinder, David, et al. "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments." The application of clinical genetics vol. 7 (2014): 55-66. doi: https://doi.org/10.2147/TACG.S58444
Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014 Apr 03;7:55-66. doi: 10.2147/TACG.S58444. eCollection 2014. PMID: 24817816; PMCID: PMC4012343.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries